KRAS and colorectal carcinoma: Cuneo et al. showed that pretreatment of cetuximab-resistant KRAS mutant CRC cell lines with crizotinib blocked radiation-induced c-MET phosphorylation, attenuated radiation-induced Akt activation, increased radiation-induced DNA damage, and prolonged DNA double-strand break repair (Cuneo et al., 2019).